Background: Thrombolytic therapy is the only approved treatment for acute cerebral ischemia. The hemorrhagic transformation is the greatest complication of this treatment, which may occur after recanalization of occluded artery. The aim of this study was to determine factors associated with clinical improvement and worsening in patients with acute ischemic stroke treated with intravenous th...

See related article, p 2922 To improve survival and ameliorate disability after ischemic stroke, many treatment modalities have been used in the acute stage of stroke. Among them, intravenous tPA (tissue-type plasminogen activator) therapy and immediate endovascular thrombectomy have improved clinical outcomes, especially in patients with severe acute ischemic stroke. Several observational stud...

INTRODUCTION Intravenous tissue plasminogen activator (IV tPA) is a globally recommended treatment for acute ischemic stroke patients. We examined IV tPA use among patients aged 18-64 years with a primary diagnosis acute ischemic stroke in the US and inpatient costs per hospitalization by IV tPA use status among these patients. METHODS Using 2010-2013 MarketScan Commercial Claims and Encounte...

BACKGROUND AND PURPOSE Emergency medical services (EMS) can effectively shorten the prehospital delay for patients with acute ischemic stroke. This study aimed to investigate EMS utilization and its associated factors in patients with acute ischemic stroke in China. METHODS A cross-sectional study was conducted from October 1, 2014, to January 31, 2015, which included 2096 patients admitted f...

Recurrent thromboembolic events after ischemic stroke in patients with cancer The authors identified 263 patients with active systemic cancer diagnosed with acute ischemic stroke at a cancer center. Despite a median survival of 84 days, 90 patients had 117 recurrent thromboembolic events. Patients with acute ischemic stroke with active cancer faced a substantial short-term risk of recurrent str...

Acute ischemic stroke results from an abrupt interruption of focal cerebral blood flow. In the majority of cases, this interruption is caused by an acute thromboembolism. Arising from the clinical trials in acute myocardial infarction, combination pharmacotherapy is gaining significant interest as a potential method to improve current thrombolytic treatment in acute ischemic stroke. This articl...

As “time is brain”, acute ischemic stroke is considered a medical emergency. With the introduction of thrombolytic therapy and availability of modern neuroimaging modalities, timely diagnosis of an ischemic lesion, exclusion of intracerebral hemorrhage, assessing the degree of brain injury, and evaluation of cerebral vasculature is necessary in acute stroke management. Various neuroimaging tech...

BACKGROUND AND PURPOSE The association of polymorphisms in the nitric oxide synthase 3 (NOS3) gene (T-786C, variable number tandem repeats 4A/B/C, and G894T) and in the methylenetetrahydrofolate reductase (MTHFR) gene (C677T) with acute ischemic stroke have been reported. METHODS First-time onset acute ischemic stroke patients (n = 120) and controls (n = 207) with no past history of stroke we...

421 Dr. V. Puetz, Department of Neurology Technical University Dresden, Fetscherstrasse 74 DE–01307 Dresden (Germany) Tel. +49 351 458 3565, Fax +49 351 458 4365 E-Mail [email protected] 9 Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group: The Desmoteplase in Acute Ischemic Strok...